GM Canada Workers Approve C$1.1 Billion Investment Deal 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Shein Shares Slide 9% in Hong Kong IPO Debut 
France Targets Shein, Temu With Fast-Fashion Fees 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
OpenAI Rejects Apple Trade Secret Theft Claims 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Add as a preferred source on Google
GAITHERSBURG, Md., March 22, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.
| Presentation Details - H.C. Wainwright Global Life Sciences Conference | ||
| Date: | Tuesday, April 10, 2018 | |
| Time: | 9:25am Eastern Time/3:25pm Central European Time | |
| Location: | LeMeridien Beach Plaza Hotel, Monte Carlo, Salon Atlantique-Meridional | |
| Webcast: | http://wsw.com/webcast/hcw2/alt/ | |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
[email protected]
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected]
